Enayet K Chowdhury1, Robyn G Langham2, Zanfina Ademi3, Alice Owen4, Henry Krum4, Lindon M H Wing5, Mark R Nelson6, Christopher M Reid4. 1. Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; enayet.chowdhury@monash.edu. 2. Department of Nephrology and University of Melbourne Department of Medicine, St. Vincent's Hospital, Melbourne, Victoria, Australia; 3. Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Melbourne EpiCentre, Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia; 4. Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; 5. School of Medicine, Flinders University, Adelaide, South Australia, Australia; and. 6. Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania, Australia.
Abstract
BACKGROUND AND OBJECTIVES: Evidence relating the rate of change in renal function, measured as eGFR, after antihypertensive treatment in elderly patients to clinical outcome is sparse. This study characterized the rate of change in eGFR after commencement of antihypertensive treatment in an elderly population, the factors associated with eGFR rate change, and the rate's association with all-cause and cardiovascularmortality. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data from the Second Australian National Blood Pressure study were used, where 6083 hypertensive participants aged ≥65 years were enrolled during 1995-1997 and followed for a median of 4.1 years (in-trial). Following the Second Australian National Blood Pressure study, participants were followed-up for a further median 6.9 years (post-trial). The annual rate of change in the eGFR was calculated in 4940 participants using creatinine measurements during the in-trial period and classified into quintiles (Q) on the basis of the following eGFR changes: rapid decline (Q1), decline (Q2), stable (Q3), increase (Q4), and rapid increase (Q5). RESULTS: A rapid decline in eGFR in comparison with those with stable eGFRs during the in-trial period was associated with older age, living in a rural area, wider pulse pressure at baseline, receiving diuretic-based therapy, taking multiple antihypertensive drugs, and having blood pressure <140/90 mmHg during the study. However, a rapid increase in eGFR was observed in younger women and those with a higher cholesterol level. After adjustment for baseline and in-trial covariates, Cox-proportional hazard models showed a significantly greater risk for both all-cause (hazard ratio, 1.28; 95% confidence interval, 1.09 to 1.52; P=0.003) and cardiovascular (hazard ratio, 1.40; 95% confidence interval, 1.11 to 1.76; P=0.004) mortality in the rapid decline group compared with the stable group over a median of 7.2 years after the last eGFR measure. No significant association with mortality was observed for a rapid increase in eGFR. CONCLUSIONS: In elderly persons with treated hypertension, a rapid decline in eGFR is associated with a higher risk of mortality.
RCT Entities:
BACKGROUND AND OBJECTIVES: Evidence relating the rate of change in renal function, measured as eGFR, after antihypertensive treatment in elderly patients to clinical outcome is sparse. This study characterized the rate of change in eGFR after commencement of antihypertensive treatment in an elderly population, the factors associated with eGFR rate change, and the rate's association with all-cause and cardiovascular mortality. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data from the Second Australian National Blood Pressure study were used, where 6083 hypertensiveparticipants aged ≥65 years were enrolled during 1995-1997 and followed for a median of 4.1 years (in-trial). Following the Second Australian National Blood Pressure study, participants were followed-up for a further median 6.9 years (post-trial). The annual rate of change in the eGFR was calculated in 4940 participants using creatinine measurements during the in-trial period and classified into quintiles (Q) on the basis of the following eGFR changes: rapid decline (Q1), decline (Q2), stable (Q3), increase (Q4), and rapid increase (Q5). RESULTS: A rapid decline in eGFR in comparison with those with stable eGFRs during the in-trial period was associated with older age, living in a rural area, wider pulse pressure at baseline, receiving diuretic-based therapy, taking multiple antihypertensive drugs, and having blood pressure <140/90 mmHg during the study. However, a rapid increase in eGFR was observed in younger women and those with a higher cholesterol level. After adjustment for baseline and in-trial covariates, Cox-proportional hazard models showed a significantly greater risk for both all-cause (hazard ratio, 1.28; 95% confidence interval, 1.09 to 1.52; P=0.003) and cardiovascular (hazard ratio, 1.40; 95% confidence interval, 1.11 to 1.76; P=0.004) mortality in the rapid decline group compared with the stable group over a median of 7.2 years after the last eGFR measure. No significant association with mortality was observed for a rapid increase in eGFR. CONCLUSIONS: In elderly persons with treated hypertension, a rapid decline in eGFR is associated with a higher risk of mortality.
Authors: Linda F Fried; Michael G Shlipak; Casey Crump; Anthony J Bleyer; John S Gottdiener; Richard A Kronmal; Lewis H Kuller; Anne B Newman Journal: J Am Coll Cardiol Date: 2003-04-16 Impact factor: 24.094
Authors: Tanvir C Turin; Josef Coresh; Marcello Tonelli; Paul E Stevens; Paul E de Jong; Christopher K T Farmer; Kunihiro Matsushita; Brenda R Hemmelgarn Journal: Kidney Int Date: 2013-01-23 Impact factor: 10.612
Authors: Tazeen H Jafar; Paul C Stark; Christopher H Schmid; Marcia Landa; Giuseppe Maschio; Paul E de Jong; Dick de Zeeuw; Shahnaz Shahinfar; Robert Toto; Andrew S Levey Journal: Ann Intern Med Date: 2003-08-19 Impact factor: 25.391
Authors: Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redón; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad Journal: J Hypertens Date: 2013-07 Impact factor: 4.844
Authors: Ron T Gansevoort; Ricardo Correa-Rotter; Brenda R Hemmelgarn; Tazeen H Jafar; Hiddo J Lambers Heerspink; Johannes F Mann; Kunihiro Matsushita; Chi Pang Wen Journal: Lancet Date: 2013-05-31 Impact factor: 79.321
Authors: Felix Mahfoud; Michael Böhm; Roland Schmieder; Krzysztof Narkiewicz; Sebastian Ewen; Luis Ruilope; Markus Schlaich; Bryan Williams; Martin Fahy; Giuseppe Mancia Journal: Eur Heart J Date: 2019-11-01 Impact factor: 29.983